![]() ![]() Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. ![]() Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. The Park City location will uniquely serve as both a clinic and a retreat center offering therapeutic psychedelic experiences, leveraging its community's reputation as a world-class destination. The Draper, Murray, and Salt Lake City locations will also offer opportunities for patients to participate in clinical trials for psychedelic medicine that are led by Cedar Clinical Research, Novamind's clinical research arm. The New Clinics will each offer a range of treatments including ketamine-assisted psychotherapy, Spravato TM, Cognitive Behavioral Therapy (CBT) and Transcranial Magnetic Stimulation (TMS). All Cedar Psychiatry clinics currently have a 2-week wait time for booking new appointments. Novamind's investment in the expansion of its clinic network follows a significant increase in demand from clients for mental health services to address existing unmet needs and the effects of the Covid-19 pandemic. Scheduled to open between July and September 2021, the New Clinics represent the initial phase of Novamind's national expansion strategy whereby the Company is replicating the successful operating track record of its current clinics in Utah, at scale, ahead of its expansion into other American states in 2021. Novamind has begun construction on three of the New Clinics and leased a fourth additional property. The expanded capacity from the New Clinics is forecasted to increase Novamind's patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits anticipated in 2021, a 325% increase. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce that it will open four new Cedar Psychiatry clinics (the "New Clinics"), doubling its network to eight total locations. TORONTO, ON / ACCESSWIRE / / Novamind Inc. New clinics represent the first phase of Novamind's national expansion strategy
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |